Chemical Engineering @ChemengFiles.Com

Kiadis Pharma has announced that Andrea Velardi, MD, Professor of Clinical Immunology at the University of Perugia (Italy) and Kiadis Pharma will continue their collaboration in ATIR (TM), a product in clinical development to enable the use of a poorly matched donor in a bone marrow transplantation by preventing graft versus host disease (GvHD) in patients with leukemia in the final phase. Under the agreement, Professor Velardi continue development of the selective reduction of donor T cells alorreactivas matched using the wrong product Kiadis Pharma, ATIR (TM). Kiadis Pharma is preparing for a pivotal multicenter study on ATIR (TM) to begin early in 2009 and Professor Velardi participate in this next study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, an eminence in the field of bone marrow transplants poorly matched," said doctorManja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR (TM) as a revolutionary approach to offer bone marrow transplants safer and poorly matched to life-saving treatment option for patients with end-stage leukemia.

Professor Andrea Velardidijo: "So far we have treated 25 patients with blood cancer who received a bone marrow donor poorly matched, including donor immune cells that selectively reduces the cells that cause acute graft versus host using process ATIR (TM). The results so far are promising and therefore I'm happy to continue working with Kiadis Pharma in this field. "